NASDAQ$GOSS
Gossamer Bio Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Gossamer Bio reported $17.0 million in revenue and a net loss of $46.7 million for the first quarter of 2026.
Gossamer Bio Inc. recorded revenue of $16.955 million from its collaboration with Chiesi during Q1 2026, primarily from research and development services and cost-sharing activities. The company reported a net loss of $46.664 million, driven by research and development expenses of $43.075 million and general and administrative expenses of $18.746 million, including costs from a workforce reduction. Cash and cash equivalents stood at $41.028 million with total assets of $128.899 million at quarter end.
- Revenue from Chiesi collaboration increased to $16.955 million, up from $9.889 million in Q1 2025, reflecting higher R&D and pre-commercial services.
- Net loss widened to $46.664 million compared to $36.638 million in the prior-year quarter, with operating expenses rising to $61.821 million.
- Company initiated a workforce reduction of 73 employees (46% of workforce) with $6.1 million in severance costs recognized in Q1.
- Cash position improved modestly to $41.028 million while maintaining focus on seralutinib development and planned NDA submission in September 2026.
Headline financials
Revenue & EPS history
Gossamer Bio · Revenue · Quarterly
$17M
Revenue by segment
Gossamer Bio · $17M total across 1 segment · Q1 2026
- Collaborators$17M—100.0%
Forward guidance
Company plans NDA submission for seralutinib in PAH in September 2026 subject to FDA feedback; workforce reduction expected to be completed by end of May 2026 with ongoing focus on resource allocation for clinical development.
Tailwinds
- Positive topline PROSERA Phase 3 data supports continued regulatory dialogue
- Chiesi collaboration provides ongoing cost-sharing and development funding
Headwinds
- Substantial doubt about ability to continue as going concern without additional funding
- PROSERA missed prespecified alpha threshold of 0.025 on primary endpoint
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
-0.6%
Avg return
Earnings day
-1.3%
Avg return
5 days after
-1.1%
Avg return
30 days after
43%
13 / 30 earnings
Positive
+15.2%
Q4 2022
Best reaction
-15.6%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | -34.9% | -50.9% | |
| Q4 2025 | -10.8% | -21.0% | -5.5% | |
| Q3 2025 | +2.2% | +16.9% | +44.2% | |
| Q2 2025 | -8.5% | -18.9% | +15.7% | |
| Q1 2025 | +1.0% | +9.5% | +18.1% | |
| Q4 2024 | +0.0% | +6.0% | -38.4% | |
| Q3 2024 | -0.9% | -4.4% | -15.1% | |
| Q2 2024 | +4.3% | +7.5% | +12.5% | |
| Q1 2024 | -3.2% | -5.0% | -23.2% | |
| Q4 2023 | +4.1% | -4.8% | -26.2% | |
| Q3 2023 | -12.0% | +4.7% | +73.1% | |
| Q2 2023 | -7.0% | -9.3% | -24.7% | |
| Q1 2023 | +3.7% | -11.8% | -7.4% | |
| Q4 2022 | +15.2% | +5.7% | -0.5% | |
| Q3 2022 | -0.8% | -4.2% | -14.9% | |
| Q2 2022 | +4.6% | +6.5% | +13.7% | |
| Q1 2022 | +12.5% | +34.2% | +9.5% | |
| Q4 2021 | +3.7% | +1.0% | -2.8% | |
| Q3 2021 | -1.4% | -9.1% | -16.6% | |
| Q2 2021 | -0.8% | +9.5% | +18.9% | |
| Q1 2021 | -0.7% | -0.7% | +1.7% | |
| Q4 2020 | -9.4% | -5.5% | -11.6% | |
| Q3 2020 | -0.9% | -1.3% | +4.2% | |
| Q2 2020 | +5.1% | +2.4% | -1.1% | |
| Q1 2020 | -15.6% | -11.5% | -27.8% | |
| Q4 2019 | +5.5% | +5.7% | +40.0% | |
| Q3 2019 | -4.3% | -1.2% | +12.4% | |
| Q2 2019 | -2.5% | +3.2% | +2.6% | |
| Q1 2019 | +1.3% | +3.7% | -3.9% | |
| Q4 2018 | -4.9% | -10.8% | -30.1% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro